Early treatment for diabetes from checkpoint inhibitors
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a medication called infliximab to see if it can help treat diabetes caused by immunotherapy (checkpoint inhibitors) used for cancer. It aims to understand how to better recognize and manage this type of diabetes early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You developed diabetes while on or within 12 months after finishing checkpoint inhibitor immunotherapy.
- Your blood sugar is high (≥200 mg/dL), or your A1c is 6.5% or higher, or your diabetes has gotten worse and you need insulin.
- You have had a measurable level of c-peptide (0.2-1 ng/mL) in your blood when your glucose was at least 145 mg/dL.
- Your overall health is good enough to participate, as determined by your doctor (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
This trial tests whether the drug infliximab can help treat kidney damage caused by immunotherapy (checkpoint inhibitors). It is for people whose kidneys suddenly fail due to inflammation, and who haven't already had strong immune-suppressing treatment for this problem.
This study looks at how certain cancer drugs (called immune checkpoint inhibitors) interact with other medicines in the body. It aims to help doctors understand how to safely combine these treatments.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
Hear when a new Pilot Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.